MOST POPULAR ARTICLES OF THE MONTH

Editor's Note

On most Saturday mornings I go out at 8 AM with our local bike club for a 30 to 40 mile ride. I usually wake up about 6 AM, and will turn on my local NPR station and tune into the People’s Pharmacy. Joe and Terry Graedon have been hosting the show for more years than Steve and I have spent at Diabetes in Control. They provide real information on a multitude of topics concerning health, and not only do they talk about drugs, they also include many natural remedies. One of the things that makes their program unique, is the researchers and medical professionals that help them explain disease states, and complementary therapies.

Last week they had Marie-Pierre St-Onge, PhD, FAHA, Associate Professor of Nutritional Medicine at Columbia
University, join them to discuss the new AHA Scientific guidelines on meal timing and how it affects many things including cholesterol. During the chat she spoke about using medications to lower LDL and how foods that were previously taboo are now acceptable. This ties in perfectly with this week’s Clinical Gem on Lipid and Lipoprotein Metabolism, Hypolipidemic Agents, and Therapeutic Goals.

EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners

Drs. Sood and Meeser talk with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the treatment methods that have brought them the most success for their patients.

CLINICAL GEMS — The Best from Diabetes Texts

In the fasting state, hepatic VLDL assembly and secretion predominate. Utilization of nascent apo B100 for the assembly and secretion of VLDL is, to a large extent, limited by substrate availability, namely TG, as apo B100 is constitutively synthesized. In the presence of adequate TG, apo B100 is progressively lipidated through the actions of hepatic MTP, and the newly assembled VLDL particle is transported to the Golgi apparatus, where it may undergo further lipidation before secretion into plasma.

MOST POPULAR ARTICLES OF THE MONTH

On most Saturday mornings I go out at 8 AM with our local bike club for a 30 to 40 mile ride. I usually wake up about 6 AM, and will turn on my local NPR station and tune into the People’s Pharmacy. Joe and Terry Graedon have been hosting the show for more years than Steve and I have spent at Diabetes in Control. They provide real information on a multitude of topics concerning health, and not only do they talk about drugs, they also include many natural remedies. One of the things that makes their program unique, is the researchers and medical professionals that help them explain disease states, and complementary therapies.

Last week they had Marie-Pierre St-Onge, PhD, FAHA, Associate Professor of Nutritional Medicine at Columbia
University, join them to discuss the new AHA Scientific guidelines on meal timing and how it affects many things including cholesterol. During the chat she spoke about using medications to lower LDL and how foods that were previously taboo are now acceptable. This ties in perfectly with this week’s Clinical Gem on Lipid and Lipoprotein Metabolism, Hypolipidemic Agents, and Therapeutic Goals.

Drs. Sood and Meeser talk with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the treatment methods that have brought them the most success for their patients.

In the fasting state, hepatic VLDL assembly and secretion predominate. Utilization of nascent apo B100 for the assembly and secretion of VLDL is, to a large extent, limited by substrate availability, namely TG, as apo B100 is constitutively synthesized. In the presence of adequate TG, apo B100 is progressively lipidated through the actions of hepatic MTP, and the newly assembled VLDL particle is transported to the Golgi apparatus, where it may undergo further lipidation before secretion into plasma.